These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 26047020

  • 21. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model.
    Pflug BR, Pecher SM, Brink AW, Nelson JB, Foster BA.
    Prostate; 2003 Nov 01; 57(3):245-54. PubMed ID: 14518031
    [Abstract] [Full Text] [Related]

  • 22. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.
    Peek EM, Song W, Zhang H, Huang J, Chin AI.
    Prostate; 2015 Apr 01; 75(5):463-73. PubMed ID: 25597486
    [Abstract] [Full Text] [Related]

  • 23. Chemopreventive Effects of Korean Angelica versus Its Major Pyranocoumarins on Two Lineages of Transgenic Adenocarcinoma of Mouse Prostate Carcinogenesis.
    Tang SN, Zhang J, Wu W, Jiang P, Puppala M, Zhang Y, Xing C, Kim SH, Jiang C, Lü J.
    Cancer Prev Res (Phila); 2015 Sep 01; 8(9):835-44. PubMed ID: 26116406
    [Abstract] [Full Text] [Related]

  • 24. 2-Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: role of tumor necrosis factor-alpha-stimulated gene 6.
    Garcia GE, Wisniewski HG, Lucia MS, Arevalo N, Slaga TJ, Kraft SL, Strange R, Kumar AP.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):980-8. PubMed ID: 16467113
    [Abstract] [Full Text] [Related]

  • 25. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
    Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM.
    Cancer Res; 1997 Aug 15; 57(16):3325-30. PubMed ID: 9269988
    [Abstract] [Full Text] [Related]

  • 26. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
    Wikström P, Lindahl C, Bergh A.
    Prostate; 2005 Feb 01; 62(2):148-64. PubMed ID: 15389804
    [Abstract] [Full Text] [Related]

  • 27. Application of the transgenic adenocarcinoma mouse prostate (TRAMP) model for pre-clinical therapeutic studies.
    Martiniello-Wilks R, Dane A, Mortensen E, Jeyakumar G, Wang XY, Russell PJ.
    Anticancer Res; 2003 Feb 01; 23(3B):2633-42. PubMed ID: 12894551
    [Abstract] [Full Text] [Related]

  • 28. Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate cancer.
    Escara-Wilke J, Keller JM, Ignatoski KM, Dai J, Shelley G, Mizokami A, Zhang J, Yeung ML, Yeung KC, Keller ET.
    Prostate; 2015 Feb 15; 75(3):292-302. PubMed ID: 25327941
    [Abstract] [Full Text] [Related]

  • 29. High animal fat intake enhances prostate cancer progression and reduces glutathione peroxidase 3 expression in early stages of TRAMP mice.
    Chang SN, Han J, Abdelkader TS, Kim TH, Lee JM, Song J, Kim KS, Park JH, Park JH.
    Prostate; 2014 Sep 15; 74(13):1266-77. PubMed ID: 25053105
    [Abstract] [Full Text] [Related]

  • 30. Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide.
    Morel KL, Ormsby RJ, Solly EL, Tran LNK, Sweeney CJ, Klebe S, Cordes N, Sykes PJ.
    Clin Exp Metastasis; 2018 Oct 15; 35(7):649-661. PubMed ID: 29936575
    [Abstract] [Full Text] [Related]

  • 31. Expression pattern of mouse homolog of prostate-specific membrane antigen (FOLH1) in the transgenic adenocarcinoma of the mouse prostate model.
    Schmittgen TD, Zakrajsek BA, Hill RE, Liu Q, Reeves JJ, Axford PD, Singer MJ, Reed MW.
    Prostate; 2003 Jun 01; 55(4):308-16. PubMed ID: 12712410
    [Abstract] [Full Text] [Related]

  • 32. 3,3'-Diindolylmethane inhibits prostate cancer development in the transgenic adenocarcinoma mouse prostate model.
    Cho HJ, Park SY, Kim EJ, Kim JK, Park JH.
    Mol Carcinog; 2011 Feb 01; 50(2):100-12. PubMed ID: 21229607
    [Abstract] [Full Text] [Related]

  • 33. The chemopreventive action of catechins in the TRAMP mouse model of prostate carcinogenesis is accompanied by clusterin over-expression.
    Caporali A, Davalli P, Astancolle S, D'Arca D, Brausi M, Bettuzzi S, Corti A.
    Carcinogenesis; 2004 Nov 01; 25(11):2217-24. PubMed ID: 15358631
    [Abstract] [Full Text] [Related]

  • 34. Magnetic resonance imaging and histopathological characterization of prostate tumors in TRAMP mice as model for pre-clinical trials.
    Degrassi A, Russo M, Scanziani E, Giusti A, Ceruti R, Texido G, Pesenti E.
    Prostate; 2007 Mar 01; 67(4):396-404. PubMed ID: 17187397
    [Abstract] [Full Text] [Related]

  • 35. Deletion of p21/Cdkn1a confers protective effect against prostate tumorigenesis in transgenic adenocarcinoma of the mouse prostate model.
    Jain AK, Raina K, Agarwal R.
    Cell Cycle; 2013 May 15; 12(10):1598-604. PubMed ID: 23624841
    [Abstract] [Full Text] [Related]

  • 36. Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers.
    Pittoni P, Tripodo C, Piconese S, Mauri G, Parenza M, Rigoni A, Sangaletti S, Colombo MP.
    Cancer Res; 2011 Sep 15; 71(18):5987-97. PubMed ID: 21896641
    [Abstract] [Full Text] [Related]

  • 37. Benzyl Isothiocyanate Inhibits Prostate Cancer Development in the Transgenic Adenocarcinoma Mouse Prostate (TRAMP) Model, Which Is Associated with the Induction of Cell Cycle G1 Arrest.
    Cho HJ, Lim DY, Kwon GT, Kim JH, Huang Z, Song H, Oh YS, Kang YH, Lee KW, Dong Z, Park JH.
    Int J Mol Sci; 2016 Feb 22; 17(2):264. PubMed ID: 26907265
    [Abstract] [Full Text] [Related]

  • 38. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model.
    Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS.
    Cancer Res; 2002 Mar 01; 62(5):1370-6. PubMed ID: 11888907
    [Abstract] [Full Text] [Related]

  • 39. Akt GSK-3 pathway as a target in genistein-induced inhibition of TRAMP prostate cancer progression toward a poorly differentiated phenotype.
    El Touny LH, Banerjee PP.
    Carcinogenesis; 2007 Aug 01; 28(8):1710-7. PubMed ID: 17468512
    [Abstract] [Full Text] [Related]

  • 40. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
    Hsieh CL, Xie Z, Yu J, Martin WD, Datta MW, Wu GJ, Chung LW.
    Prostate; 2007 May 15; 67(7):685-91. PubMed ID: 17342752
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.